Repetitive Transcranial Magnetic Stimulation As Treatment of Poststroke Depression: a Preliminary Study
Overview
Authors
Affiliations
Background: Depression has a significant impact on poststroke recovery and mortality. There are a proportion of patients with poststroke depression (PSD) who do not respond to antidepressants. Repetitive Transcranial Magnetic Stimulation (rTMS) might be a safe and effective alternative in these refractory cases.
Methods: We conducted a randomized, parallel, double-blind study of active versus sham left prefrontal rTMS in patients with refractory PSD. After discontinuing antidepressants, patients were randomly assigned to receive 10 sessions of active (10 Hz, 110% of the motor threshold, 20 trains of 5 seconds duration) or sham left prefrontal rTMS. Efficacy measures included HAM-D scores, response and remission rates. Patients completed a neuropsychological battery at baseline and after completing the protocol.
Results: When compared with sham stimulation, 10 sessions of active rTMS of the left dorsolateral prefrontal cortex were associated with a significant reduction of depressive symptoms. This reduction was not influenced by patient's age, type or location of stroke, volume of left frontal leukoaraiosis or by the distance of the stimulating coil to the prefrontal cortex. However, there was a significant positive correlation between the percentage of reduction of Ham-D scores and frontal gray and white matter volumes. There were no significant changes in cognitive functioning between the active and the sham stimulation groups. In addition, there were few and mild adverse effects that were equally distributed among groups.
Conclusions: Taken together, these preliminary findings suggest that rTMS may be an effective and safe treatment alternative for patients with refractory depression and stroke.
Goke K, McClintock S, Mah L, Rajji T, Lee H, Nestor S Can J Psychiatry. 2025; :7067437251315515.
PMID: 39881587 PMC: 11783421. DOI: 10.1177/07067437251315515.
Stress-Induced Auto-Cannibalism in Patients With a History of Moderate Traumatic Brain Injury.
Fenati G, Youssoffi S, Phan D, McManus K, Dong F, Neeki M Cureus. 2023; 15(6):e41232.
PMID: 37529515 PMC: 10387508. DOI: 10.7759/cureus.41232.
Allida S, Hsieh C, Cox K, Patel K, Rouncefield-Swales A, Lightbody C Cochrane Database Syst Rev. 2023; 7:CD003437.
PMID: 37417452 PMC: 10327406. DOI: 10.1002/14651858.CD003437.pub5.
Sheng R, Chen C, Chen H, Yu P Front Immunol. 2023; 14:1197422.
PMID: 37283739 PMC: 10239808. DOI: 10.3389/fimmu.2023.1197422.
Klingbeil J, Brandt M, Stockert A, Baum P, Hoffmann K, Saur D Front Neurol. 2023; 14:1144228.
PMID: 37265471 PMC: 10231644. DOI: 10.3389/fneur.2023.1144228.